Blog
18 Articles
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
Research: The Next Generation
AACR young researchers come from all over the world, and add their perspectives to pancreatic cancer studies.
Steely Strength to Keep Going
Long-term survivor Davi D’Agostino discovered she carries the BRCA2 mutation, which changed her treatment plan to targeted therapy.
A Long Journey That Began With Pancreatitis
Paul Suntup’s diagnosis of acinar cell pancreatic cancer was just the start of a long treatment journey, but he’s still here.
Targeting Pancreatic Cancer Cell Growth
Researchers are testing a new drug targeting cell growth in solid tumors, including pancreatic cancer.
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
Targeted Therapy for Cancers Carrying the PALB2 Mutation
Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.
Blood-Based Test Predicts What Drugs May Work Best
Dr. Kenneth Yu is testing a blood-based assay that looks at which types of chemotherapies will work best for each pancreatic cancer patient.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Harnessing the Power of Radionuclide Therapy
Julie Sutcliffe is working with targeted radionuclide therapy to go after pancreatic cancer cells that have spread beyond the pancreas.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.